Table 3

Crude and adjusted HR associated with collagen markers for early (90-day) and late (365-day) clinical outcomes

	PIIINP (high vs low)				P4NP 7S (high vs low)
	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value	Unadjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
Primary outcome measure
Cardiac death and admission for HF	1.19 (0.83 to 1.73)	0.34	0.78 (0.52 to 1.16)	0.23	1.20 (0.83 to 1.73)	0.34	1.50 (1.02 to 2.21)	0.04
Landmark analysis within 90 days	1.09 (0.65 to 1.81)	0.75	0.79 (0.46 to 1.38)	0.42	1.69 (1.02 to 2.86)	0.04	1.89 (1.11 to 3.26)	0.02
Landmark analysis beyond 90 days	1.25 (0.78 to 2.02)	0.35	0.84 (0.50 to 1.40)	0.5	0.96 (0.59 to 1.54)	0.86	1.26 (0.76 to 2.07)	0.37
Secondary outcome measures
Admission for HF	1.14 (0.77 to 1.69)	0.5	0.71 (0.47 to 1.09)	0.12	1.33 (0.90 to 1.97)	0.15	1.66 (1.11 to 2.51)	0.01
Cardiac death	0.93 (0.41 to 2.08)	0.86	0.76 (0.31 to 1.79)	0.52	1.02 (0.46 to 2.24)	0.97	1.20 (0.51 to 2.76)	0.68
All-cause death	1.38 (0.84 to 2.29)	0.2	1.15 (0.67 to 1.97)	0.62	0.80 (0.49 to 1.32)	0.39	1.07 (0.63 to 1.79)	0.8

In the multivariable Cox proportional hazards models, age, sex, EF<40% and eGFR were incorporated as risk-adjusting variables.
EF, ejection fraction; eGFR, estimated glomerular filtration rate; HF, heart failure.